Current and historical daily PS Ratio for Pfizer Inc (
) from 1990 to Jul 21 2026. The price to sales ratio is calculated by taking the current stock price and dividing it by the trailing twelve-month sales per share. The data is updated every 20 minutes during market hours. The PS ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS ratio is a great valuation tool for evaluating cyclical businesses where the PE ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean. Pfizer stock (PFE) PS ratio as of Jul 21 2026 is 2.24.
More Details
Pfizer Inc (PFE) PS Ratio Chart
Pfizer Inc (PFE) PS Ratio Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1207
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Pfizer PS Ratio Historical Data | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date | PS Ratio Data | Date | PS Ratio Data | ||||||
| 2026-07-21 | 2.2 | 2.26 | 2.22 | 2.25 | 2026-05-14 | 2.4 | 2.36 | 2.32 | 2.32 |
| 2026-07-20 | 2.3 | 2.27 | 2.23 | 2.23 | 2026-05-13 | 2.3 | 2.35 | 2.31 | 2.34 |
| 2026-07-17 | 2.3 | 2.31 | 2.25 | 2.26 | 2026-05-12 | 2.3 | 2.35 | 2.32 | 2.33 |
| 2026-07-16 | 2.3 | 2.29 | 2.24 | 2.27 | 2026-05-11 | 2.3 | 2.36 | 2.32 | 2.33 |
| 2026-07-15 | 2.2 | 2.24 | 2.19 | 2.24 | 2026-05-08 | 2.4 | 2.36 | 2.31 | 2.32 |
| 2026-07-14 | 2.2 | 2.2 | 2.18 | 2.19 | 2026-05-07 | 2.4 | 2.41 | 2.36 | 2.39 |
| 2026-07-13 | 2.2 | 2.23 | 2.19 | 2.21 | 2026-05-06 | 2.4 | 2.41 | 2.37 | 2.39 |
| 2026-07-10 | 2.2 | 2.2 | 2.17 | 2.18 | 2026-05-05 | 2.4 | 2.41 | 2.35 | 2.39 |
| 2026-07-09 | 2.2 | 2.19 | 2.17 | 2.19 | 2026-05-04 | 2.4 | 2.39 | 2.36 | 2.37 |
| 2026-07-08 | 2.2 | 2.2 | 2.16 | 2.17 | 2026-05-01 | 2.4 | 2.4 | 2.37 | 2.38 |
| 2026-07-07 | 2.2 | 2.2 | 2.16 | 2.17 | 2026-04-30 | 2.4 | 2.43 | 2.37 | 2.41 |
| 2026-07-06 | 2.2 | 2.18 | 2.13 | 2.14 | 2026-04-29 | 2.4 | 2.4 | 2.36 | 2.37 |
| 2026-07-02 | 2.2 | 2.22 | 2.18 | 2.19 | 2026-04-28 | 2.5 | 2.49 | 2.38 | 2.39 |
| 2026-07-01 | 2.2 | 2.19 | 2.14 | 2.16 | 2026-04-27 | 2.4 | 2.47 | 2.42 | 2.42 |
| 2026-06-30 | 2.2 | 2.21 | 2.15 | 2.17 | 2026-04-24 | 2.4 | 2.46 | 2.4 | 2.44 |
| 2026-06-29 | 2.2 | 2.21 | 2.18 | 2.2 | 2026-04-23 | 2.4 | 2.42 | 2.38 | 2.41 |
| 2026-06-26 | 2.1 | 2.2 | 2.14 | 2.19 | 2026-04-22 | 2.5 | 2.47 | 2.41 | 2.42 |
| 2026-06-25 | 2.2 | 2.2 | 2.13 | 2.14 | 2026-04-21 | 2.5 | 2.49 | 2.45 | 2.46 |
| 2026-06-24 | 2.2 | 2.27 | 2.16 | 2.17 | 2026-04-20 | 2.5 | 2.51 | 2.48 | 2.48 |
| 2026-06-23 | 2.3 | 2.28 | 2.23 | 2.23 | 2026-04-17 | 2.5 | 2.5 | 2.45 | 2.49 |
| 2026-06-22 | 2.3 | 2.28 | 2.25 | 2.26 | 2026-04-16 | 2.5 | 2.48 | 2.45 | 2.46 |
| 2026-06-18 | 2.3 | 2.32 | 2.25 | 2.28 | 2026-04-15 | 2.5 | 2.47 | 2.43 | 2.45 |
| 2026-06-17 | 2.4 | 2.37 | 2.33 | 2.34 | 2026-04-14 | 2.5 | 2.46 | 2.44 | 2.45 |
| 2026-06-16 | 2.4 | 2.36 | 2.32 | 2.35 | 2026-04-13 | 2.4 | 2.49 | 2.41 | 2.47 |
| 2026-06-15 | 2.4 | 2.38 | 2.34 | 2.35 | 2026-04-10 | 2.5 | 2.47 | 2.42 | 2.43 |
| 2026-06-12 | 2.4 | 2.39 | 2.36 | 2.37 | 2026-04-09 | 2.5 | 2.48 | 2.45 | 2.46 |
| 2026-06-11 | 2.3 | 2.39 | 2.33 | 2.36 | 2026-04-08 | 2.5 | 2.48 | 2.43 | 2.48 |
| 2026-06-10 | 2.3 | 2.33 | 2.31 | 2.31 | 2026-04-07 | 2.5 | 2.5 | 2.42 | 2.45 |
| 2026-06-09 | 2.3 | 2.34 | 2.3 | 2.32 | 2026-04-06 | 2.5 | 2.55 | 2.51 | 2.51 |
| 2026-06-08 | 2.3 | 2.37 | 2.31 | 2.31 | 2026-04-02 | 2.6 | 2.59 | 2.55 | 2.56 |
| 2026-06-05 | 2.3 | 2.37 | 2.33 | 2.35 | 2026-04-01 | 2.5 | 2.58 | 2.53 | 2.58 |
| 2026-06-04 | 2.3 | 2.35 | 2.31 | 2.32 | 2026-03-31 | 2.5 | 2.56 | 2.51 | 2.53 |
| 2026-06-03 | 2.3 | 2.31 | 2.28 | 2.29 | 2026-03-30 | 2.5 | 2.51 | 2.45 | 2.51 |
| 2026-06-02 | 2.3 | 2.32 | 2.28 | 2.31 | 2026-03-27 | 2.5 | 2.53 | 2.47 | 2.47 |
| 2026-06-01 | 2.3 | 2.34 | 2.3 | 2.31 | 2026-03-26 | 2.5 | 2.54 | 2.49 | 2.52 |
| 2026-05-29 | 2.4 | 2.37 | 2.34 | 2.36 | 2026-03-25 | 2.5 | 2.51 | 2.47 | 2.49 |
| 2026-05-28 | 2.4 | 2.37 | 2.35 | 2.36 | 2026-03-24 | 2.4 | 2.48 | 2.41 | 2.46 |
| 2026-05-27 | 2.3 | 2.39 | 2.33 | 2.37 | 2026-03-23 | 2.5 | 2.48 | 2.43 | 2.44 |
| 2026-05-26 | 2.3 | 2.34 | 2.32 | 2.33 | 2026-03-20 | 2.5 | 2.51 | 2.45 | 2.46 |
| 2026-05-22 | 2.4 | 2.36 | 2.32 | 2.34 | 2026-03-19 | 2.5 | 2.53 | 2.49 | 2.5 |
| 2026-05-21 | 2.3 | 2.34 | 2.31 | 2.34 | 2026-03-18 | 2.5 | 2.5 | 2.45 | 2.49 |
| 2026-05-20 | 2.3 | 2.35 | 2.32 | 2.33 | 2026-03-17 | 2.5 | 2.53 | 2.45 | 2.5 |
| 2026-05-19 | 2.3 | 2.34 | 2.28 | 2.32 | 2026-03-16 | 2.4 | 2.45 | 2.42 | 2.43 |
| 2026-05-18 | 2.3 | 2.29 | 2.27 | 2.29 | 2026-03-13 | 2.5 | 2.49 | 2.42 | 2.43 |
| 2026-05-15 | 2.3 | 2.33 | 2.28 | 2.29 | 2026-03-12 | 2.5 | 2.47 | 2.43 | 2.45 |
Pfizer Inc (PFE) PS Ratio Comparison
| Company | Market Cap(Mil) | PS Ratio |
|---|
Business Description
Business Description
Pfizer Inc
NAICS : 325412
SIC : 2834
ISIN : US7170811035
Share Class Description:
PFE: Ordinary SharesTotal Employee Number:
75,000Compare
Compare
Traded in other countries / regions
PFE.USAPFE.Canada0Q1N.UKPFE.GermanyPFE.ArgentinaPFE.MexicoPFIZ34.Brazil1PFE.ItalyPFE.AustriaPFE_KZ.KazakhstanPFE.SwitzerlandPFE.PeruPFE.BulgariaPFE.ChilePFECO.ColombiaPFE.Ukraine Index Membership
S&P 500Russell 1000Russell 3000MSCI World IndexDow 30 IPO Date
1951-06-22Description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.